The price has dropped, and how to implement the results of national centralized procurement has become the key. One of the reasons for the high cost of medical treatment reported by the people is the inflated prices of some drugs and consumables. The national organization of centralized procurement of drugs and high-value medical consumables is aimed at squeezing out the "water" in inflated prices and effectively reducing the burden of medical treatment on patients. Since the implementation of national centralized procurement, the prices of selected drugs and consumables have significantly decreased. The price has dropped, and how to implement the results of centralized procurement has become the key. To enable patients to enjoy national policy benefits in a timely manner, it is not enough to rely solely on a certain department or region. It is necessary to gather the efforts of various parties such as medical insurance, healthcare, drug supervision, medical institutions, and selected enterprises. Everyone must adopt effective transportation methods to ensure that the results of collective procurement can be felt and enjoyed by the people. Medical insurance departments at all levels are the organizers of centralized procurement, as well as the main responsible persons and contacts for implementing the results of centralized procurement, with a heavy burden. On the one hand, in conjunction with the health department, it is necessary to guide and supervise medical institutions at all levels to prioritize the selection of selected products through centralized procurement, and encourage departments and doctors to prioritize the issuance and use of selected products. Therefore, it is recommended that the medical insurance department provide more scientific guidance for hospitals to fill out procurement plans, complete the plans on time and in accordance with the quantity, and establish corresponding reward and punishment mechanisms. It is suggested that the health department further standardize the hospital's assessment system, clarify the quantity and proportion of products selected through centralized procurement. In clinical practice, we will continue to strengthen rational drug use management through measures such as prescription review, spot checks, pharmaceutical services, and medication monitoring. On the other hand, the medical insurance department should work together with the drug regulatory department to ensure the quality and safety of the selected products. Strict technical standards, full coverage supervision and inspection of selected enterprises, and full coverage sampling inspection of selected products. We need to steadily promote traceability management and achieve traceability throughout the entire process of centralized procurement products after they are launched. Medical institutions at all levels should increase their enthusiasm and awareness of using centralized procurement products. For hospitals, lowering the originally inflated prices of drugs and consumables can effectively reduce the proportion of drugs and consumption; In the context of payment by disease group and disease type, the use of centralized procurement products with unified pricing can standardize and visualize the clinical diagnosis and treatment process, help control unreasonable growth of medical expenses, and save medical insurance funds. Of course, medical institutions can also actively provide feedback on usage and offer suggestions for enriching the collection of products based on clinical and patient needs. The selected enterprise should supply products with quality and quantity in accordance with the requirements of the procurement contract. To maintain real-time communication and contact with medical institutions, increase stocking efforts according to clinical demand, and ensure delivery is in place; To ensure that product quality meets technical requirements in accordance with medical device laws, regulations, and production quality management standards, and to achieve 'price reduction without compromising quality'. The medical insurance department and medical institutions should also fully consider the reasonable profit demands of enterprises, shorten the payment settlement cycle, so that enterprises have sufficient funds to invest in scientific research, and form a virtuous cycle of promoting research and development through centralized procurement, improving products through research and development, and further enriching centralized procurement. (New Society)